Literature DB >> 10859445

Stage migration in clinically localized prostate cancer.

J Noldus1, M Graefen, A Haese, R P Henke, P Hammerer, H Huland.   

Abstract

OBJECTIVES: To determine whether migration of pathological tumor stages in patients with clinically localized prostate cancer exists and whether this is due to an increasing frequency of treating patients with clinically insignificant cancer.
METHODS: 1,063 radical retropubic prostatectomies were performed in patients with clinically localized prostate cancer in one institution within 7.5 years (from 1992 until June 1999). All specimens were prospectively processed according to the Stanford protocol. These were then analyzed regarding the migration of pathological tumor stages and cancer volumes.
RESULTS: Within the observation period, the annual rate of radical retropubic prostatectomies increased by 225% from 69 to 224 cases. The authors noted a decline of advanced tumor stages (from 65 to 40%) and an increase in pathological T2 tumors (from 30 to 55%). The rate of small cancers (<0.5 cm(3)) remained stable between 2 and 5% over the last 5 years.
CONCLUSION: The data confirm trends which were observed in large US centers with increasing detection and treatment of localized prostate cancer without unnecessary treatment of clinically insignificant cancers.

Entities:  

Mesh:

Year:  2000        PMID: 10859445     DOI: 10.1159/000020255

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  19 in total

1.  Seed implant brachytherapy for prostate cancer.

Authors:  D D'Souza; M J Zelefsky
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

Review 2.  [Indications for and results of radical prostatectomy].

Authors:  M Graefen; P G Hammerer; A Haese; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

3.  [Influence of transrectal endosonography on the clinical staging of impalpable prostate cancer. A controversy over the TNM system].

Authors:  P G Hammerer; H Augustin; J Blonski; M Graefen; A Haese; A Erbersdobler; F Daghofer; H Huland
Journal:  Urologe A       Date:  2004-03       Impact factor: 0.639

4.  Is prostate cancer stage migration continuing for black men in the PSA era?

Authors:  R W Dobbs; D T Greenwald; H Wadhwa; V L Freeman; M R Abern
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-17       Impact factor: 5.554

5.  Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population.

Authors:  Yasuhiro Hashimoto; Akiko Okamoto; Atsushi Imai; Tohru Yoneyama; Shingo Hatakeyama; Takahiro Yoneyama; Takuya Koie; Noritaka Kaminura; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2011-06-16       Impact factor: 3.402

Review 6.  Overdiagnosis and overtreatment of prostate cancer.

Authors:  Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni
Journal:  Eur Urol       Date:  2014-01-09       Impact factor: 20.096

7.  Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer.

Authors:  Felix K-H Chun; Markus Graefen; Mario Zacharias; Alexander Haese; Thomas Steuber; Thorsten Schlomm; Jochen Walz; Pierre I Karakiewicz; Hartwig Huland
Journal:  World J Urol       Date:  2006-02-28       Impact factor: 4.226

Review 8.  Value of multiparametric MRI in the work-up of prostate cancer.

Authors:  F Cornud; N B Delongchamps; P Mozer; F Beuvon; A Schull; N Muradyan; M Peyromaure
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

9.  [Prostate-specific antigen for treatment monitoring].

Authors:  M Graefen; M Fröhner; M Wirth
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

10.  Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.

Authors:  Geng Zhang; Hongtao Zhang; Qiang Wang; Priti Lal; Ann M Carroll; Margarita de la Llera-Moya; Xiaowei Xu; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.